

# Visual outcomes using a comanaged and open access method for the Light Adjustable Lens® in cataract surgery

<b>Submission date</b> 20/04/2022	<b>Recruitment status</b> No longer recruiting	<input type="checkbox"/> Prospectively registered <input checked="" type="checkbox"/> Protocol
<b>Registration date</b> 28/04/2022	<b>Overall study status</b> Completed	<input type="checkbox"/> Statistical analysis plan <input checked="" type="checkbox"/> Results
<b>Last Edited</b> 04/01/2023	<b>Condition category</b> Eye Diseases	<input type="checkbox"/> Individual participant data

## Plain English summary of protocol

### Background and study aims

To assess the safety and effectiveness of cataract surgery using the Light Adjustable Lens (LAL) using two doctors, co-managing for each patient. The surgeon will do the surgery and a medical provider will do light treatments to the LAL to further improve vision after surgery. Surgery and light treatments will be done in different locations. Light treatments will be done in a facility that is open access for patients of other surgeons.

### Who can participate?

Patients that have cataracts, wanting the LAL and do not have any diseases of the macula or cornea.

### What does the study involve?

Having cataract surgery and using the LAL as the IOL implant at the time of the cataract surgery. It will involve up to 5 follow-up light treatments to adjust the power of the LAL after surgery to further improve the patient's vision.

### What are the possible benefits and risks of participating?

The benefits would include improved vision from correction of the cataract and improved vision from correction of refractive error (glasses) through adjustment of the power of the LAL after surgery. All surgery and testing are "standard of care" with no "study specific" surgery or tests performed. Risks are related to those of cataract surgery including vision loss and the need for additional surgery.

### Where is the study run from?

It is run from the surgery center where cataract surgery is performed and the TCEC LASIK Center where the post-op light treatments are performed (USA)

### When is the study starting and how long is it expected to run for?

July 2021 to January 2022

Who is funding the study?  
Investigator initiated and funded

Who is the main contact?  
David V. Folden, MD  
foldav@gmail.com

## Contact information

**Type(s)**  
Principal Investigator

**Contact name**  
Dr David Folden

**ORCID ID**  
<http://orcid.org/0000-0002-9912-7719>

**Contact details**  
10452 Vermillion Cir NE  
Blaine  
United States of America  
55449  
+1 612-396-9574  
dfolden@nseyespecialists.com

## Additional identifiers

**EudraCT/CTIS number**  
Nil known

**IRAS number**

**ClinicalTrials.gov number**  
Nil known

**Secondary identifying numbers**  
7459325

## Study information

**Scientific Title**  
Novel care delivery model for the RxSight Light Adjustable Lens®: a co-managed, open-access methodology

**Acronym**  
NCDM LAL CoMOA

**Study objectives**

Using a comanaged arrangement at an open access facility, use of the Light Adjustable Lens in cataract surgery is safe and efficacious.

### **Ethics approval required**

Old ethics approval format

### **Ethics approval(s)**

Ethics approval is not required given its retrospective chart review design, confirmed by Salus IRB.

### **Study design**

Observational retrospective case series

### **Primary study design**

Observational

### **Secondary study design**

Case series

### **Study setting(s)**

Other

### **Study type(s)**

Treatment

### **Participant information sheet**

Not applicable (retrospective study)

### **Health condition(s) or problem(s) studied**

Use of the Light Adjustable Lens in patients with cataracts and receiving cataract surgery

### **Interventions**

Observational retrospective case series chart review of a consecutive series of patients in a private practice setting between July 2021 and January 2022.

The visual acuities, manifest refractions, and adverse events were evaluated in the charts of patients that underwent cataract surgery using the light adjustable lens. Data was extracted from the patient's final postoperative visit sometime between 3 and 9 months postoperatively.

### **Intervention Type**

Other

### **Primary outcome measure**

Collected by retrospective chart review between 3 and 9 months postoperatively:

1. Uncorrected monocular and binocular distance
2. Near visual acuities
3. Safety

### **Secondary outcome measures**

Collected by retrospective chart review between 3 and 9 months postoperatively:

1. Manifest refraction

**Overall study start date**

01/07/2021

**Completion date**

31/01/2022

## Eligibility

**Key inclusion criteria**

Patients who received cataract surgery and management of their Light Adjustable Lens using a comanaged approach at an open access facility.

**Participant type(s)**

Patient

**Age group**

Adult

**Sex**

Both

**Target number of participants**

32

**Total final enrolment**

32

**Key exclusion criteria**

1. Retinal or macular disease
2. Clinically significant corneal abnormalities
3. Corneal scarring
4. Ectasia

**Date of first enrolment**

01/07/2021

**Date of final enrolment**

31/01/2022

## Locations

**Countries of recruitment**

United States of America

**Study participating centre**

**North Metro Surgery Center**

11855 Ulysses Street, Suite 270

Blaine

United States of America  
55434

**Study participating centre**

**TCEC LASIK Center**

3601 76th Street W, Suite #150  
Edina  
United States of America  
55435

## **Sponsor information**

**Organisation**

North Suburban Eye Specialists

**Sponsor details**

3777 Coon Rapids Blvd NW Suite 100  
Coon Rapids  
United States of America  
55443  
+1 763-421-7420  
ahalabi@nseyespecialists.com

**Sponsor type**

Industry

**Website**

<http://www.nseyespecialists.com>

## **Funder(s)**

**Funder type**

Other

**Funder Name**

Investigator initiated and funded

## **Results and Publications**

Publication and dissemination plan

Planned publication in a high-impact peer-reviewed journal.

### Intention to publish date

01/07/2022

### Individual participant data (IPD) sharing plan

The datasets will be de-identified with no PHI patient specific data being used in the analysis. Any raw data generated during the current study are not expected to be made available unless requested by the publication source after the manuscript is submitted.

### IPD sharing plan summary

Not expected to be made available

### Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
<a href="#">Protocol file</a>			27/04/2022	No	No
<a href="#">Results article</a>		04/08/2022	04/01/2023	Yes	No